MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

319,58

01-ноября-24 14:59:58

15 мин. задержка

Акции

+60,24

+23,23%

Сегодняшний диапазон

262,85 - 321,19

ISIN

N/A

Источник

NASDAQ

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 ноя 2023 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

28 сен 2023 21:30:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Proposed Public Offering

28 сен 2023 15:01:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 сен 2023 15:30:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

13 сен 2023 08:10:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

11 сен 2023 06:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

08 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

17 июл 2023 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

30 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

22 июн 2023 02:30:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Supports International NASH Day on June 8

06 июн 2023 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

01 июн 2023 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

11 май 2023 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

09 май 2023 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

18 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

23 фев 2023 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

08 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

06 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.